Research Article

LC-MS/MS Quantification of Tramadol and Gabapentin Utilizing Solid Phase Extraction

Pappula Nagaraju,1 Balaji Kodali,2 Peda Varma Datla,3 and Surya Prakasarao Kovvasu4

1Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur 522002, Andhra Pradesh, India
2College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar 522510, Guntur, Andhra Pradesh, India
3Clinical Pharmacology and Bio Sciences Division, RA Chem Pharma, Hyderabad, India
4College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA

Correspondence should be addressed to Pappula Nagaraju; pappulanagaraju@gmail.com

Received 11 March 2018; Revised 11 June 2018; Accepted 11 July 2018; Published 28 October 2018

Academic Editor: Barbara Bojko

Copyright © 2018 Pappula Nagaraju et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

An accurate, highly sensitive, and precise method for quantitative analysis of tramadol (TMD) and gabapentin (GBP) by high performance liquid chromatography and tandem mass spectrometry in human plasma was proposed and validated successfully using venlafaxine and pregabalin as internal standards (ISDs), respectively. An aliquot of 200 μL of plasma was mixed with internal standard dilution and extraction was performed by using solid phase extraction (SPE) technique. Peak resolution was achieved on Phenomenex PFP column (50×4.6 mm, 2.6 μm). The total analytical run time was 3.8 min. Both analytes were monitored using multiple reaction monitoring (MRM) scan and the mass spectrometer was operated in positive polarity mode. The method was validated for specificity, sensitivity, precision, accuracy, and other analytical parameters. The results found were satisfactory over the linear calibration range of 1-500 ng/mL and 10-6000 ng/mL for TMD and GBP, respectively. The developed method can be ready to use by scientific community for quantification of analytes in plasma samples from various clinical studies of different dose strengths.

1. Introduction

Tramadol hydrochloride (TMD), chemically (+)-trans-2-[(dimethyl-amino) methyl]-1-(3-methoxyphenyl) cyclohexanol, is a central analgesic agent for the treatment of severe moderate to chronic pain. Tramadol is also considered as an alternate to opiates for neuropathic pains. Tramadol also proves to produce antitussive, antidepressant, anti-inflammatory, and immune stimulatory effects [1, 2]. In humans, TMD metabolized by cytochrome P4502D6 to its phase I metabolites, namely, O-desmethyltramadol and N-desmethyltramadol. These are again metabolized to N,N-didesmethyltramadol, N,N,O-tridesmethyltramadol, and N, O-desmethyllumtramadol then further produce sulfate and glucuronic acid conjugates before excretion via kidneys in urine [3–5]. TMD is selective opiate agonist at μ-opioid receptors and inhibits reuptake of norepinephrine and serotonin [6]. TMD has plasma protein binding of about 20% and is rapidly absorbed with bioavailability of 65-70% after oral administration [7, 8]. As per the literature search, the analytical methods available for estimation of TMD with its desmethylates in plasma including liquid chromatography coupled to ultraviolet (UV) detector [9–11], fluorescence detector [12, 13], and tandem mass spectrometry (MS/MS) [14–22] are well reported.

Gabapentin (GBP), 1-(aminomethyl-1-cyclohexyl) acetic acid, is a structural analog of the inhibitory neurotransmitter amino butyric acid (GABA) which is a new generation effective antiepileptic drug for partial epileptic seizures with or without secondary generalization [23–25]. The GBP mechanism of action was not clearly defined, but described cellular actions are likely to be related to multiple concentration-dependent actions resulting in supremacy over seizure control [26]. It has been observed that GBP bioavailability varies
greatly (inter- and intrasubjects) due to its active absorption by gut and renal excretion of unchanged drug. The bioavailability of a 600 mg oral dose was 49%; individual subjects may vary greatly from 5% to 74% [27, 28]. Gabapentin was proved to be beneficial in the treatment of neuropathic pain as well as postoperative pain following spinal surgery and hysterectomy [29]. Gabapentin in neuropathic pain models prevents mechanical and thermal allodynia and mechanical hyperalgesia. Though the mechanism of action of gabapentin in the treatment of neuropathic pain is not clear, it does not influence the same pathways as opioids or tricyclic depressants. Current evidence indicates that gabapentin affects voltage-gated calcium channels in the CNS [30, 31]. It was also reported that GBP was also effective in pain management because of neuralgia, diabetic neuropathy, multiple sclerosis, and neuropathic cancer pain in miscellaneous reports [32]. Several analytical methods were reported for the determination of GBP that includes high performance liquid chromatography (HPLC) coupled ultraviolet (UV) [33, 34], fluorescence detection [35], and mass spectrometry (MS) [36–42].

Fixed dose combination (FDC) of TMD with paracetamol for pain management in patients was available in market. The TMD combination with GBP is the present choice for doctors to treat pain carried by healthy nerves because of damaged tissues and damaged nerves (neuropathic). In present days, different combinations of TMD and GBP along with other analgesics like ibuprofen are under investigation [43]. The individual dosage forms for TMD and GBP were available around the globe but the FDC (TMD+ GBP) is commonly available in Latin America. The phase-IV clinical or bioequivalence studies are necessary for FDC approvals. Since no method was reported so far for simultaneous determination of TMD and GBP in human plasma, hence we aimed to develop specific and selective achiral assay for quantification of TMD and GBP in human plasma as per USFDA [44] and EMEA [45] bioanalytical method validation guidelines. The biological TMD metabolites (desmethylates) measurement was not required to prove bioequivalence as per major health regulatory bodies; hence only parent drugs (TMD, GBP) are considered for method development. Finally, highly sensitive and repeatable method was developed for quantification of analytes in human plasma, useful to assess either efficacy or toxicity of both TMD and GBP (particularly) in various clinical situations. The present method is able to quantify the TMD and GBP at very low level (i.e., LLOQ 1 ng/mL and 10 ng/mL), which means that the established linear range is suitable to monitor TMD and GBP circulating levels across the relevant clinical range up to five terminal half-lives (t1/2), right from administration to approximate elimination (trough and subclinical concentrations) from the body [21, 22, 38].

2. Experimentation

2.1. Reference Standards and Reagents. The high purity reference standards of TMD, GBP, venlafaxine (VFX), and pregabaline (PGB) were procured from Clearsynth Labs Pvt. Ltd. (Mumbai, India). The HPLC grade methanol and acetonitrile are purchased from Thermo Fisher Scientific India Pvt. Ltd. (Mumbai, India). GR grade ammonium formate and ammonium acetate reagents were procured from Merck Specialities Pvt. Ltd. (Mumbai, India). Milli-Q water was collected from Milli-Q A10 gradient water purification system (Millipore, Bedford, MA, USA). Strata-X polymeric extraction cartridges (30 mg, 1 cc) for solid phase extraction (SPE) are purchased from Phenomenex India Pvt. Ltd.

2.2. Analytical Instrumentation. An ultra flow prominence high performance liquid chromatography (UF-HPLC) coupled with tandem mass spectrometer (MS/MS-3200 model, Sciex, Canada) was used for analysis. The mass spectrometer was assembled with electro spray ionization (ESI) interface. The HPLC was supplied with LC-20AD binary pumps, 20A3 solvent degasser, column oven, and high-throughput SIL HTC auto sampler. After chromatographic separation, the positive polarity MS detection was performed in multiple reaction monitoring (MRM) mode. Analyst software 1.5.1 platform was used for data collection and hardware controlling.

2.3. Chromatographic Conditions. Analytical peak resolution was achieved on a Phenomenex, Kinetex PFP column (C18, 50 × 4.6 mm, 5 μm) pumped with isocratic mobile phase consisting a mixture of 5 mM ammonium formate buffer (pH 3.0 ± 0.3), acetonitrile, and methanol in the ratio of 25: 50: 25 v/v. The flow rate was 0.8 mL/min. The auto sampler and column oven were programmed to maintain the set temperatures at 5°C and 35°C, respectively. Sample volume of 10 μL was injected into the LC-MS/MS system. The total analytical run was 3.8 min.

2.4. MS/MS Compound and Source Dependent Conditions. The mass spectrometer was operated in positive mode to monitor parent→product ion (m/z) transitions of analytes (TMD, GBP) and their internal standards (ISTDs) (VFX, GBP). The specific details of MRM transitions and their respective mass spectrometer voltage values like declustering potential (DP), entrance potential (EP), collision energy (CE), and collision exit potential (CXP) used for quantification of respective analytes and ISTDs are summarized in Table 1. Manual tuning was performed to optimize the source dependent and compound dependent parameters to get highest credible intensities. The source dependent parameters like drying gas (GSi) and nebulizer gas (GS2) were set at 35 psi, 45Psi duly. The turbo ion spray (TIS) temperature and ion spray voltage were set at 500°C and 4,500 V, respectively. The curtain gas (CUR) and collision associated dissociation gas (CAD) pressure were maintained at 30 psi and 8 psi. The unit resolution mode was employed in Q1 and Q3 (quadrupoles) with a dwell time of 300 milliseconds.

2.5. Standard Curve and Control Samples. Stock solutions of TMD and GBP were prepared in methanol and respective working (spiking) dilutions were made using diluent solution of methanol: water mixture (50:50, v/v). Separate stock weighing was done for preparation of calibration curve and quality control stock solutions. Calibration curves in range
of 1-500 ng/mL and 10-6000 ng/mL were prepared for TMD and GBP, respectively. Quality control samples were made at concentration of 1 ng/mL lower limit of quality control (LLOQC), 3 ng/mL lower quality control (LQC), 212 ng/mL middle quality control (MQC), 380 ng/mL high quality control (HQC), 1000 ng/mL diluted quality control (DQC) for TMD and 10 ng/mL (LLOQC), 30 ng/mL (LQC), 2500 ng/mL (MQC), 4500 ng/mL (HQC), and 12000 ng/mL (DQC) for GBP. The 1% of respective working dilution was spiked into the total volume of plasma (for example, 10µL of working solution was added to 990µL of plasma, which is 1% to the total volume) to get above-mentioned concentrations for both the analytes. The long-term plasma stability samples at LQC and HQC level were prepared and stored at -70 °C in ploy propylene tubes. The spiked samples were prepared freshly based on the validation experimentation plan. All the stock solutions and working dilutions were stored in refrigerator maintained at 2-8 °C.

2.6. Bio Analytical Extraction Procedure. 200 µL of plasma sample was aliquoted using micropipette in to a 6mL polypropylene tube containing 100 µL of ISTD solution (containing each 500 ng/mL of VFX and PGB) and then 0.2 mL of 100 mM ammonium acetate buffer as pretreatment solution was added. The resultant sample was briefly mixed and subjected to positive pressure solid phase extraction procedure using strata-X cartridges (30 mg/1 cc). The samples were loaded on cartridges which were already preconditioned with 1mL methanol and 1 mL Milli-Q water. Followed by loading, cartridge was washed with 1 mL 0.1% formic acid, 1 mL n-Hexane, and 1 mL methanol:water (5:95 v/v) solution step by step. Allow the cartridges to dry for about 3 min and then elute with 1 mL of 2% ammoniated methanol solution. The eluent solution was evaporated to dryness under gentle stream of nitrogen at a pressure of 20psi and at temperature of 50 °C. The residue was reconstituted with 400 µL of mobile phase and 10 µL was injected into chromatographic system for analysis.

3. Method Validation

The developed method was validated to ensure method performance. The method was validated as per USFDA and EMEA guidelines. Method sensitivity, selectivity, linearity, precision, accuracy, recovery, matrix effect, dilution integrity, and analyte stability in biological matrix were evaluated. Each analytical run in validation begins with calibration curve and evenly distributed quality control samples at different levels based on standard experimental requirements.

| Name of the molecule | MRM Transition (Q1/Q3) | DP | EP | CE | CXP |
|----------------------|------------------------|----|----|----|-----|
| TMD                  | 264.2/58.1             | 50 | 10 | 22 | 15  |
| GBP                  | 172.2/154.2            | 38 | 10 | 27 | 10  |
| VFX                  | 278.3/121.1            | 70 | 10 | 27 | 8   |
| PGB                  | 160.2/971              | 90 | 10 | 23 | 11  |

### 3.1. System Suitability

Two injections of low standard solution and six injections of high standard solution containing both analytes (TMD, GBP) were injected to ensure system conditions. The low standard solution was injected to check the peak shape. The % CV for area ratio (analyte/ ISTD for both TMD, GBP) of high standard solution should be less than 4.

### 3.2. Biological Matrix Screening and Selectivity

The percentage of interference due to exogenous and endogenous components at retention times of analytes and ISTD was evaluated by processing eight different lots of blank plasma along with each two lots of hemolytic and lipemic plasma.

The interference due to concomitant medication at retention time was also investigated by spiking paracetamol, ibuprofen, ranitidine, and ondansetron into drug free plasma at concentration equal to their available literature Cmax values. The interference observed at the retention times of analytes and ISTDs in blank plasma lots was compared against mean response of extracted LLOQ (n=6) samples. The observed interference should be less than 20% and 5% at analyte and ISTD retention times, respectively, when compared to mean response of extracted LLOQ samples.

### 3.3. Reproducibility (Precision) and Accuracy

At four different quality control levels (LLOQC, LQC, MQC, and HQC, n=12) within day (intrabatch) and between day (interbatch, n=24) precision and accuracy of TMD, GBP was evaluated by calculating the %CV and %accuracy. In together six reproducibility batches were performed on two different days by two different analysts.

### 3.4. Effect of Matrix

The signal suppression or enhancement via ionization should be studied in mass spectrometric detection methods. To prove that, the method is free from matrix effect, postextraction response from 10 different lots (including each two lots of hemolytic and lipemic plasma) were compared with response of aqueous samples. The matrix effect was evaluated at LQC, HQC levels by calculating matrix factor of analyte and ISTD. Later ISTD normalized matrix factor was calculated by using matrix factor of analyte and ISTD. If ISTD normalized matrix factor value is 1, that indicates there is no suppression or enhancement due to the presence of matrix. If the value is less than 1, that indicates ion suppression or more than 1, that indicates ion enhancement. The acceptable limits for ISTD normalized matrix factor are 0.85-1.15.

### 3.5. Linearity of Analytes

The method linearity was assessed by constructing three eight-point calibration curves. A linear
4. Results and Discussion

4.1. Method Development. For efficient quantification and reliable results, it is prerequisite to give equal importance to optimize the chromatographic conditions, extraction procedure and mass spectrometric conditions. All analytes dissolved in methanol, individually infused into MS (mass spectrometer) source for tuning and then selected positive mode because of better intensity. The Q1 scan was performed to select the parent ion. The declustering potential (DP), entrance potential (EP) voltage values were further optimized to get highest intensity for parent ion. After that, collision energy (CE), collision cell exit potential (CXP) values were optimized in MSMS scan to select product ion for TMD, GBP, PGB and VFX. The observed [M+H]+ peaks (parent ion) and respective consistent product ions were selected for mass spectrometric transitions (Q1/Q3) in MRM (multiple reaction monitoring) mode for quantification. The selected transitions and optimized voltage values were shown in Table 1. The unit resolution mode with a dwell time of 300 milliseconds was used for each MRM transition channel.

Several analytical bonded stationary phases of C18 and C8 were checked and retention times of analytes are overlapped. Initially, aqueous solution of LLOQ level was injected into normal gemini C18 (50 × 4.6 mm, 5 μm) column, but the observed peak resolution was not good and peak intensity is very low, the identical chromatogram of LLOQ solution in gemini column was shown in Figure 1. Then sample solution was injected into thermo high purity C18 (100 × 4.6 mm, 3.5 μm), column to improve the peak shape. The observed peak resolution was comparatively good with low intensity. The representative chromatogram was shown in Figure 2. The better peak shape and resolution with required sensitivity was achieved on Phenomenex, PFP (50 × 4.6 mm, 2.6 μm) column may be because of its combining C18 retention properties and unique aromatic PFP selectivity.
strength buffer 5 mM ammonium formate gives high signal to noise ratio with negligible baseline noise at LLOQ level.

In sample extraction, liquid-liquid and solid phase extraction techniques were investigated. In liquid-liquid extraction high base line was observed because of possible matrix contaminants. The representative chromatogram is shown in Figure 3. Finally, solid phase extraction was selected due to its high consistent extraction recoveries with no matrix effect and cleaner extracts. Phenomenex Strata-X cartridges with 5% methanol wash produced side peaks in chromatography and low recovery was observed with GBP. An acidic wash with 0.1% formic acid increases the GBP recovery, followed by n-hexane wash to eliminate nonpolar interferences prior to the elution resolved the side peaks issue. Method was strictly optimized to get similar recoveries for analytes and ISTDs. The nearly same % recovery results for analytes and ISTDs with acceptable ISTD normalized factor values of the method assure reproducible quantification.

4.2 Selectivity. Eight plasma lots along with each two different lots of hemolytic and lipemic plasma were processed and injected for LC-MS/MS analysis. Similar chromatography was observed with no significant interference at the retention times of analytes and ISTDs in all analyzed blank lots, which indicates that the developed method was highly selective.

4.3 Linearity. Three calibration curves were generated by plotting the area ratios (analyte response/ ISTD response) on y-axis and concentration on x-axis. The plot was linear throughout the established calibration ranges, 1-500 ng/mL for TMD and 10-6000 ng/mL for GBP. The slope values are consistent and regression values were...
found to be more than 0.99. The back calculated concentrations for individual calibration standards are meeting acceptance criteria for accuracy (±15 %) and precision (≤15 %).

4.4. Sensitivity. Six replicates of LLOQ samples were processed and analyzed against calibration curve. The accuracy and precision values were 91.3 % and 3.8 % for TMD and 98.6 % and 2.9 % for GBP. The observed signal to noise ratio is more than 5:1 for both the analytes.

4.5. Precision and Accuracy. Accuracy and reproducibility results of intra- and interbatches of TMD and GBP were reported in Tables 2 and 3, respectively. The intra- and interbatch accuracy values were in the range of 92.3%-99.2% and intra and interbatch precision were found to be less than 10.9 % and 6.7 % for TMD and GBP. The chromatogram at LLOQ level was shown in Figure 4.

4.6. Effect of Matrix. In general consideration, effect of matrix does not influence peak resolution due to MS selectivity.
Table 4: Matrix effect results of TMD and GBP.

| Blank plasma lots | TMD (ISNMF) | GBP (ISNMF) |
|------------------|-------------|-------------|
|                  | LQC         | HQC         | LQC         | HQC         |
| LOT-1            | 0.99        | 0.96        | 0.93        | 1.02        |
| LOT-2            | 0.98        | 0.97        | 0.94        | 1.05        |
| LOT-3            | 0.98        | 0.96        | 0.92        | 0.94        |
| LOT-4            | 0.97        | 0.95        | 0.96        | 0.98        |
| LOT-5            | 1.02        | 0.99        | 0.99        | 0.96        |
| LOT-6            | 1.01        | 1.06        | 0.97        | 0.97        |
| LOT-7 hemolytic  | 0.99        | 1.01        | 0.98        | 0.99        |
| LOT-8 hemolytic  | 1.03        | 0.99        | 0.96        | 1.04        |
| LOT-9 lipemic    | 0.98        | 0.94        | 0.96        | 0.94        |
| LOT-10 lipemic   | 0.99        | 0.97        | 0.94        | 0.96        |
| Mean             | 0.994       | 0.980       | 0.955       | 0.985       |
| SD               | 0.0196      | 0.0350      | 0.0222      | 0.0395      |
| %CV              | 2.0         | 3.6         | 2.3         | 4.0         |

ISTDNMF: internal standard normalised matrix factor.

Table 5: Recovery results of TMD and GBP.

| Sample name     | % Mean recovery absolute | % Mean recovery relative |
|-----------------|--------------------------|-------------------------|
|                 | TMD                      | GBP                     |
|                 |                          | TMD                      | GBP                      |
| LQC             | 81.5                     | 83.5                    | 83.8                     | 86.4                     |
| MQC             | 78.4                     | 80.5                    | 81.2                     | 82.1                     |
| HQC             | 84.7                     | 79.9                    | 78.9                     | 82.2                     |
| VFX at MQC level| 85.4                     |                         | 79.1                     |                          |
| PGB at MQC level| 81.9                     |                         | 82.4                     |                          |

4.7. Recovery. Absolute and relative recovery of analytes and ISTDs was evaluated. The mean recovery results of TMD, GBP, VFX, and PGB are represented in Table 5.

4.8. Dilution Integrity. Precision and accuracy of diluted plasma samples were assessed at 1:4 dilution. The DQC (dilution quality control) was prepared by spiking at a concentration equal to two times of high level calibration standard of proposed range for TMD and GBP, respectively. Then 1/4th volume of plasma aliquot was diluted with drug free plasma and analyzed against calibration curve. The accuracy values were in the range of 92.4%-106.5 % and %CV was less than 3.2% for TMD and GBP.

4.9. Stability. All the stock solutions and stock dilutions were stable for 21 days at refrigerated storage maintained at 2-8°C. The processed stability samples in plasma at LQC and HQC levels were analyzed against freshly prepared calibration curve. The stability data results are given in Table 6. TMD and GBP were stable in plasma at room temperature for about 16 h and for 5 freeze and thaw cycles. The established stability time for TMD and GBP was 41 h and 52 h for auto sampler and dry extract stabilities. The analytes were found to be stable for 2.5 h in blood. The long-term stability was evaluated and analytes were stable for 32 days at −70°C.

5. Conclusion

Full method validation was carried out using screened and pooled human plasma to ensure that developed procedure is accurate and precise for estimation of TMD and GBP simultaneously. The high-throughput LC-ESI-MS/MS method is sensitive and specific. The recovery, precision, and accuracy results were reproducible over the proposed calibration ranges for TMD and GBP. The shorter runtime allows the analysis of more samples (~300) per day. The method can be readily used by scientific community for the application of sample analysis for therapeutic monitoring/pharmacokinetic or bioequivalence studies.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors are thankful to Praveen Datla, Clinical Research and Bio Sciences, Hyderabad, India, for their continuous support, motivation, and assistance during the course of this project.

References

[1] B. Kukanich and M. G. Papich, "Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs," Journal of Veterinary Pharmacology and Therapeutics, vol. 27, pp. 239–246, 2004.

[2] I. Yalein, F. Aksu, and C. Belzung, "Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol," European Journal of Pharmacology, vol. 514, pp. 165–174, 2005.

[3] K. Miotto, A. K. Cho, M. A. Khalil, K. Blanco, J. D. Sasaki, and R. Rawson, "Trends in tramadol: pharmacology, metabolism, and misuse," Anesthesiology & Analgesia, vol. 124, no. 1, pp. 44–51, 2017.

[4] W. S. James and D. N. Young, "Tramadol," Cmaj, vol. 185, no. 8, p. E352, 2013.

[5] W. Leppert, "CYP2D6 in the metabolism of opioids for mild to moderate pain," Pharmacology, vol. 87, no. 5–6, pp. 274–285, 2011.

[6] L. Poulsen, L. Arendt-Nielsen, K. Broesen, and S. H. Sindrup, "The hypoalgesic effect of tramadol in relation to CYP2D6," Clinical Pharmacology & Therapeutics, vol. 60, no. 6, pp. 636–644, 1996.

[7] S. Groud and A. Sablotzki, "Clinical Pharmacology of Tramadol," Clinical Pharmacokinetics, vol. 43, no. 13, pp. 879–923, 2004.

[8] W. Lintz, H. Barth, R. Becker, E. Frankus, and E. Schmidt-Bothelt, "Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations-2nd communication: Drops with ethanol," Arzneimittel-Forschung, vol. 48, no. 5, pp. 436–445, 1998.

[9] L. Qu, S. Feng, Y. Wu, and S. Da, "HPLC method for determination of tramadol hydrochloride in human plasma," Journal of Sichuan University. Medical Science Edition = Sichuan Daxue Xuebao (Yixue Ban), vol. 34, no. 3, pp. 574–575, 2003.

[10] G. C. Yeh, M. T. Sheu, C. L. Yen, Y. W. Wang, C. H. Liu, and H. O. Ho, "High-performance liquid chromatographic method for determination of tramadol in human plasma," Journal of Chromatography B: Biomedical Sciences and Applications, vol. 723, pp. 247–253, 1999.

[11] S. H. Gan, R. Ismail, W. A. A. Adnan, and Z. Wan, "Method development and validation of a high-performance liquid chromatographic method for tramadol in human plasma using liquid–liquid extraction," Journal of Chromatography B, vol. 772, pp. 123–129, 2002.

[12] H. Ebrahimzadeh, Y. Yamini, A. Sedighi, and M. R. Rouini, "Determination of tramadol in human plasma and urine samples using liquid phase microextraction with back extraction combined with high performance liquid chromatography," Journal of Chromatography B, vol. 863, no. 2, pp. 229–234, 2008.

[13] A. Curticapean, D. Muntean, M. Curticapean, M. Dogaru, and C. Vara, "Optimized HPLC method for tramadol and O-desmethyl tramadol determination in human plasma," Journal of Biochemical and Biophysical Methods, vol. 70, no. 6, pp. 1304-1312, 2008.

[14] M. J. Bogusz, R.-D. Maier, K.-D. Krüger, and U. Kohls, "Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography-atmospheric-pressure chemical-ionization mass spectrometry," Journal of Analytical Toxicology, vol. 22, no. 7, pp. 594–598, 1998.

[15] A. Ceccato, F. Vanderbist, and B. Streel, "Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography–tandem mass spectrometry," Journal of Chromatography B: Biomedical Sciences and Applications, vol. 748, no. 1, pp. 65–76, 2000.

[16] B. N. Patel, N. Sharma, M. Sanyal, and P. S. Shrivastav, "An accurate, rapid and sensitive determination of tramadol and its active metabolite O-desmethyltramadol in human plasma by LC–MS/MS," Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 2, pp. 354–366, 2009.

[17] M. Gergov, P. Nokua, E. Vuori, and J. Ojanperä, "Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography-tandem mass spectrometry," Forensic Science International, vol. 186, pp. 36–43, 2009.

[18] M. De Leo, M. Giorgi, G. Saccomanni, C. Manera, and A. Braca, "Evaluation of tramadol and its main metabolites in horse plasma by high-performance liquid chromatography/fluorescence and liquid chromatography/electrospray ionization tandem mass spectrometry techniques," Rapid Communications in Mass Spectrometry, vol. 23, no. 2, pp. 228–236, 2009.

Table 6: Stability results of TMD and GBP.

| Stability experiment       | Stability condition | TDL LQC | TDL HQC | FNS LQC | FNS HQC |
|----------------------------|---------------------|---------|---------|---------|---------|
| Auto sampler stability     | 41 h at 5°C         | 98.1    | 96.4    | 96.1    | 106.7   |
| Free and thaw stability    | 5 cycles at -70°C ± 15°C | 97.1   | 100.1   | 99.9    | 96.1    |
| Dry extract stability      | 52 h at 2-8°C       | 94.8    | 96.8    | 101.2   | 96.6    |
| Room temperature stability | 16 h at room temperature at 25°C ± 5°C | 94.1   | 102.8   | 91.7    | 97.2    |
| Long term stability        | 32 days at -70°C ± 15°C | 99.6   | 95.7    | 98.8    | 95.5    |
| Stability in blood         | 2.5 h room temperature at 25°C ± 5°C | 96.4   | 99.1    | 103.2   | 97.6    |
[19] N. V. de Moraes, G. R. Lauretti, M. N. Napolitano et al., "Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC–MS/MS: Application to clinical pharmacokinetics," Journal of Chromatography B, vol. 880, pp. 140–147, 2012.

[20] G. Saccomanni, S. Del Carlo, M. Giorgi, C. Manera, A. Saba, and M. Macchia, "Determination of tramadol and metabolites by HPLC-FI and HPLC-MS/MS in urine of dogs," Journal of Pharmaceutical and Biomedical Analysis, vol. 53, pp. 194–199, 2010.

[21] L. Vlase, S. E. Leucuta, and S. Imre, "Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection," Talanta, vol. 75, no. 4, pp. 1049–1059, 2008.

[22] T. Hironari, N. Takafumi, M. Yasuaki, and J. Kawakami, "Validated determination method of tramadol and its desmethylates in human plasma using an isocratic LC-MS/MS and its clinical application to patients with cancer pain or non-cancer pain," Journal of Pharmaceutical Health Care and Sciences, vol. 2, no. 25, pp. 1–9, 2016.

[23] M. C. Walker and P. N. Patsalos, "Clinical pharmacokinetics of new antiepileptic drugs," Pharmacology & Therapeutics, vol. 67, no. 3, pp. 351–384, 1995.

[24] P. Gareri, T. Gravina, G. Ferreri, and G. De Sarro, "Treatment of epilepsy in the elderly Prog Neurobiol," Journal of the Korean Medical Association, vol. 58, no. 5, pp. 398–407, 1999.

[25] R. K. Berlin, P. M. Butler, and M. D. Perloff, "Gabapentin therapy in psychiatric disorders: A systematic review," Primary Care Companion to the Journal of Clinical Psychiatry, vol. 17, no. 5, 2015.

[26] M. J. McLean, "Gabapentin in the management of convulsive disorders," Epilepsia, vol. 40, no. 6, pp. S39–S50, 1999.

[27] B. E. Gidal, L. L. Radulovic, S. Kruger, P. Rutecki, M. Pitterle, and H. N. Bockbrader, "Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability," Epilepsy Research, vol. 40, no. 2–3, pp. 123–127, 2000.

[28] D. Ouellet, H. N. Bockbrader, D. L. Wescbe, D. Y. Shapiro, and E. Garofalo, "Population pharmacokinetics of gabapentin in infants and children," Epilepsy Research, vol. 47, no. 3, pp. 229–241, 2001.

[29] C. W. Goodman and A. S. Brett, "Gabapentin and Pregabalin for Pain—Is Increased Prescribing a Cause for Concern?" The New England Journal of Medicine, vol. 377, pp. 411–414, 2017.

[30] M. A. Rose and P. C. Kam, "Gabapentin: pharmacology and its use in pain management," Anaesthesia, vol. 57, no. 5, Article ID 451462, pp. 431–462, 2002.

[31] C. Y. Chang, C. K. Challa, J. Shah, and J. D. Eloy, "Gabapentin in Acute Postoperative Pain Management," BioMed Research International, vol. 2014, Article ID 631756, 7 pages, 2014.

[32] J. Mao and L. L. Chen, "Gabapentin in Pain Management," Anesthesia & Analgesia, vol. 91, pp. 680–687, 2000.

[33] G. L. Lensmeyer, T. Kempf, B. Gidal, and D. Weibe, "Optimized method for determination of gabapentin in serum by HPLC," Ther Drug Monit, vol. 17, pp. 251–258, 1995.

[34] Z. Zhu and L. Neirinck, "High-performance liquid chromatographic method for the determination of gabapentin in human plasma," Journal of Chromatography B, vol. 779, pp. 307–312, 2002.

[35] Q. Jiang and S. Li, "Rapid high-performance liquid chromatographic determination of serum gabapentin," Journal of Chromatography B: Biomedical Sciences and Applications, vol. 727, no. 1-2, pp. 119–123, 1999.